Medigene (ETR:MDG1) Shares Down 0.7%

Medigene AG (ETR:MDG1) shares fell 0.7% on Thursday . The company traded as low as €1.80 ($1.97) and last traded at €1.80 ($1.97). 5,784 shares traded hands during trading, a decline of 98% from the average session volume of 306,207 shares. The stock had previously closed at €1.81 ($1.99).

Medigene Price Performance

The company has a current ratio of 2.39, a quick ratio of 5.85 and a debt-to-equity ratio of 12.94. The stock has a market cap of $28.48 million, a PE ratio of -1.60, a P/E/G ratio of 7.12 and a beta of 0.84. The company’s 50 day moving average is €1.30 and its 200-day moving average is €1.46.

Medigene Company Profile

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.